Novartis AG - Stock Based Compensation

Novartis AG's Fiscal Year is From January To December - All Figures are in USD, Billions.

The item "Stock-Based-Compensation" stands at 1.07 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value at least since 03/31/2013, the period currently displayed.

Novartis AG's third quarter result of 0.268 Billion USD for the item "Stock Based Compensation" represents an increase of 0.37 percent compared to it's second quarter result.

Also, Novartis AG's third quarter result of 0.268 Billion USD for the item "Stock Based Compensation" represents an increase of 5.10 percent compared to it's third quarter result of last year.

Looking again at the trailing twelve months series (TTM), Novartis AG's third quarter result of 1.07 Billion USD for the item "Stock Based Compensation" represents an increase of 1.23 percent compared to it's second quarter result.


Regarding the One-Year-Change of the series, the current value constitutes an increase of 4.80 percent compared to the value the year prior.
The 1 year change in percent is 4.80.
The 3 year change in percent is 30.21.
The 5 year change in percent is 42.72.
The 10 year change in percent is 6.16.

The Serie's long term average value is 0.871 Billion United States Dollars. It's latest available value, on 09/30/2025, is 22.78 percent higher, compared to it's long term average value.
The Serie's change in percent from it's minimum value, on 12/31/2017, to it's latest available value, on 09/30/2025, is +75.53%.
The Serie's change in percent from it's maximum value, on 09/30/2025, to it's latest available value, on 09/30/2025, is 0.0%.